NASDAQ:ONC BeOne Medicines Q2 2025 Earnings Report $359.41 -2.37 (-0.65%) As of 09:49 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast BeOne Medicines EPS ResultsActual EPS$0.84Consensus EPS $0.48Beat/MissBeat by +$0.36One Year Ago EPSN/ABeOne Medicines Revenue ResultsActual Revenue$1.32 billionExpected Revenue$1.24 billionBeat/MissBeat by +$76.45 millionYoY Revenue GrowthN/ABeOne Medicines Announcement DetailsQuarterQ2 2025Date8/6/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile BeOne Medicines Earnings HeadlinesBeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare ConferenceSeptember 1 at 8:01 AM | finance.yahoo.comBeOne Medicines Reaches US Accord on Drug Access, Domestic ManufacturingAugust 31 at 11:48 PM | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 3 at 1:00 AM | Banyan Hill Publishing (Ad)BeOne Medicines' Tacabrutideg Presents 'Sizable Opportunity' in CSU, RBC SaysAugust 25, 2026 | finance.yahoo.comBeOne Medicines and partners renew Brukinsa access programme for CLLAugust 19, 2026 | finance.yahoo.comBeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and ...August 18, 2026 | tmcnet.comSee More BeOne Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email. Email Address About BeOne MedicinesBeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.View BeOne Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestLilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond ObesityWendy’s Rally Fades After Trian Steps Back: Was It Ever Real?From High Dividend Growth to High Yield, These 3 Stocks Just Boosted Dividend PayoutsJ.M. Smucker Stock's Rally Has More Than Tariffs Behind ItUlta Beauty’s Earnings Beat Was Stronger Than the Stock’s ReactionNVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
